https://www.selleckchem.com/products/apx2009.html
Administration of ALN-F12 resulted in dose-dependent reductions of both liver F12 mRNA and plasma FXII protein. In mice, ALN-F12 led to dose-dependent reductions in platelet and fibrin accumulation in the venous electrolytic-injury model and in the time to occlusion in the ferric chloride arterial thrombosis model. At 10mg/kg ALN-F12, the top dose level evaluated, this resulted in 95% reduction of FXII and ~10 fold reduction in fibrin deposition. Finally, hemostasis models showed that 95% reduction of FXII had no impact on bleed
Like
Comment
Share
